United Therapeutics: The Stock Is Priced for Stagnation. The Filings Tell a Different Story.
Two facts about United Therapeutics sit side by side right now and refuse to make peace....
Biogen: The Stock That Priced In a Recovery the Margins Haven’t Filed Yet
Five years ago, Biogen's stock briefly traded above $425 on the back of an Alzheimer's drug...
Elanco Is Earning More Than It Ever Has. The Stock Is Priced Like That’s Just the Beginning.
The quick read Elanco's filed numbers show a business that spent five years losing money and...
Viatris: The Stock Is Up 55% in a Year. The Revenue Has Fallen Every Year Since 2021.
Before anything else The math, meaning what the filed numbers justify, shows a company whose top...
The Golden Arches at a Discount: What $271 Assumes McDonald’s Will Never Do Again
Six years ago, McDonald's was a pandemic-battered company selling coffee and fries to a world that...
Gilead’s Books Say One Thing. The Price Tag Says Another. Here’s What the Filings Actually Show.
A company reports an operating loss of more than $10 billion in a single quarter. Its...
The Price That Needs a Perfect Harvest
Deere's stock is priced for a margin peak the filings say hasn't arrived yet. That gap...
Starbucks Is Earning More Per Customer Than It Has in Years. The Stock Is Priced as If That’s Just the Beginning.
In one breath The filed numbers show a business climbing out of a genuine hole: four...
Bank of America Is Priced for a Bank It Has Never Quite Been
The stock is trading near a decade high. The earnings multiple sits at its 81st percentile...
UPS: The Margin Story the Filings Tell vs. the One the Market Is Buying
A stock trading at a trailing earnings multiple well above its own decade average. A business...
BullScope is an evidence-first investment research publication. Every note starts in the filings: what companies actually report, what the market assumes, and where the two disagree. We read the numbers so you can read the story. Not investment advice.